NewcelX Ltd. (NCEL) News
Follow NewcelX Ltd. (NCEL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
RCL completes $1.25 billion senior unsecured notes offering
RCL completes its offering of $1.25 billion senior unsecured notes due 2034; the wire also lists secondary-stock offering and registration items for AVAH, BKV, NCEL and PYXS.
RATES | Aug 21, 2026, 10:59 AM UTC
H
NCEL Prices $1.4M Equity Financing
NCEL prices equity financing at 20% premium
EQUITY | Jul 31, 2026, 01:00 PM UTC
L
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ: ELDN ) anti-CD40L antibody, tegoprubart, an
REGULATION | Jul 01, 2026, 01:33 PM UTC